Annual report pursuant to Section 13 and 15(d)

Business (Details)

v3.20.4
Business (Details)
1 Months Ended 12 Months Ended
Jun. 11, 2020
USD ($)
Jan. 31, 2021
USD ($)
Apr. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
product
offering
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Subsequent Event [Line Items]            
Number of equity offerings | offering       3    
Net proceeds     $ 12,800,000 $ 44,400,000   $ 5,700,000
Cash and cash equivalents       18,919,448 $ 3,609,438  
Net (loss) income       (63,499,772) (16,072,547)  
Net cash used in operating activities       (40,539,700) (19,134,332)  
Accumulated deficit       $ (177,790,389) $ (114,290,617)  
Underwritten Public Offering            
Subsequent Event [Line Items]            
Net proceeds $ 35,400,000          
Subsequent Event | Underwritten Public Offering            
Subsequent Event [Line Items]            
Net proceeds   $ 37,600,000        
Neurological Clinical And Preclinical Stage Compounds            
Subsequent Event [Line Items]            
Number of products in development | product       2    
Clinical Stage            
Subsequent Event [Line Items]            
Number of products in development | product       4